111247-94-0

Basic information

• Product Name: 3-O-decladinosyl-9-deoxo-9a-aza-9a-homoerythromycin A
• Synonyms: 3-O-decladinosyl-9-deoxo-9a-aza-9a-homoerythromycin A
• CAS NO: 111247-94-0
• Molecular Weight: 576.772
• Mol File: 111247-94-0.mol
• Article Data: 0

Chemical Properties

• Melting Point: 146-151°C
• CAS DataBase Reference: 3-O-decladinosyl-9-deoxo-9a-aza-9a-homoerythromycin A(CAS DataBase Reference)
• NIST Chemistry Reference: 3-O-decladinosyl-9-deoxo-9a-aza-9a-homoerythromycin A(111247-94-0)
• EPA Substance Registry System: 3-O-decladinosyl-9-deoxo-9a-aza-9a-homoerythromycin A(111247-94-0)

Safety Data

• Hazardous Substances Data: 111247-94-0(Hazardous Substances Data)

Usage

Description

3-O-decladinosyl-9-deoxo-9a-aza-9a-homoerythromycin A is a modified derivative of erythromycin A, an azalide macrolide antibiotic. It is characterized by the removal of the cladinose sugar at the 3-O position and the presence of a nitrogen atom at the 9a position, which replaces the oxygen atom in the parent compound. This modification results in a unique structure with distinct properties and potential applications.

Uses

Used in Pharmaceutical Industry:
3-O-decladinosyl-9-deoxo-9a-aza-9a-homoerythromycin A is used as an antibiotic agent for the treatment of bacterial infections. Its unique structure and properties may provide enhanced antimicrobial activity, improved pharmacokinetics, and reduced potential for drug resistance compared to conventional macrolide antibiotics.
Used in Research and Development:
3-O-decladinosyl-9-deoxo-9a-aza-9a-homoerythromycin A serves as a valuable compound for research and development in the field of medicinal chemistry. Its unique structure allows for further exploration of the structure-activity relationship of macrolide antibiotics, leading to the discovery of novel and more effective antimicrobial agents.
Used in Drug Delivery Systems:
Similar to gallotannin, 3-O-decladinosyl-9-deoxo-9a-aza-9a-homoerythromycin A can be incorporated into drug delivery systems to improve its therapeutic efficacy and bioavailability. Various carriers, such as organic and metallic nanoparticles, can be employed to enhance the delivery of this modified erythromycin derivative to target sites, thereby improving its overall effectiveness in treating bacterial infections.

Downstream Products

• 1417891-03-2 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-[(phenylmethoxy)carbonyl]-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one